A phase II study of pemetrexed plus carboplatin followed by pemetrexed maintenance therapy in chemotherapy-naive elderly patients with non-squamous non-small cell lung cancer - A phase II study of pemetrexed plus carboplatin followed by pemetrexed maintenance therapy in chemotherapy-naive elderly patients with non-squamous non-small cell lung cancer

Yokohama City University Medical Center0 个研究点目标入组 43 人开始时间: 2011年3月9日最近更新: 2023年10月17日

试验速览

阶段: 2 期
状态: 已完成
发起方: Yokohama City University Medical Center
入组人数: 43

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

The 1-year survival rate was 73%(95% confidence interval(CI)56_84%).RR was 43.9%,DCR was 80.5%,median PFS was 7.23 months(95%CI 3.98_9.20), and median OS was 17.41 months(95%CI 13.60_22.83).Twenty-one patients(51.2%)were transitioned to aintenance therapy.Carboplatin and pemetrexed followed by maintenance pemetrexed for non-squamous non-small cell lung cancer in elderly patients was effective and tolerable.

研究设计

研究类型: Observational

入排标准

年龄范围: 70years-old 至 85years-old（—）
性别: All

入选标准

未提供

排除标准

•1.Interstitial pneumonia or pulmonary fibrosis detectable on CT scan. 2.Patients with active co-morbidities including severe conditions. *uncontrollable angina pectoris, myocardial infarction within 3 months, severe heart disease. *uncontrollable diabetes, hypertension. *severe infection *paresis of intestine, illeus *Patients whose participation in the trial is judged to be inappropriate by the attending doctor. 3.Patients with massive pleural and cardiac effusion and ascites that need to be immediately treated. 4.Brain metastases with neurological symptoms. 5.SVC syndrome. 6.Active double cancer. 7.Pregnancy, breast feeding and suspected pregnancy. 8.History of grave drug allergic reaction. 9.Psychiatric disorder. 10.Patients whose participation in the trial is judged to be inappropriate by the attendeing doctor.

研究者

发起方

Yokohama City University Medical Center

相似试验

招募中

2 期

A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancer (EGFR mutation status Negative)

JPRN-UMIN000005991Toho University Omori Medical Center35

已完成

2 期

A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed Plus Bevacizumab in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancer

JPRN-UMIN000003770Osaka Lung Cancer Study Group40

已完成

1 期

A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung CancerNon-Small-Cell Lung Cancer

NCT00482014Eli Lilly and Company120

已完成

2 期

A Phase II study of Pemetrexed plus Carboplatin followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancer

JPRN-UMIN000003755Dept. of Respiratory Medicine, Osaka University Hospital40

已完成

2 期

Phase 2 study of Pemetrexed + Carboplatin as first line therapy for non-squamous non-small cell lung cancer without EGFR Mutation (CJLSG0906)

JPRN-UMIN000003393Central Japan Lung Study Group53